Please login to the form below

Not currently logged in
Email:
Password:

MEDI8897

This page shows the latest MEDI8897 news and features for those working in and with pharma, biotech and healthcare.

US, EU regulators back rapid reviews of AZ’s RSV med

US, EU regulators back rapid reviews of AZ’s RSV med

MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Sanofi paid 120m upfront for a share in MEDI8897 last year with another 495m in development and

Latest news

  • AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

    There’s also provision for up to $470m in sales milestones ties to Synagis, plus a $175m payment due on the US filing for MEDI8897 and another $170m ties to sales ... The Synagis and MEDI8897 deals continues AZ’s policy of focusing firmly on a few

  • Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

    Sanofi is already active in this category after licensing rights to AstraZeneca’s phase II candidate MEDI8897 last year, with both projects aimed at providing treatment for already-established RSV infections.

  • Regeneron drops RSV drug Regeneron drops RSV drug

    The failure of suptavumab to hit the mark in the NURSERY study removes a potential rival for AstraZeneca's RSV candidate MEDI8897 - recently partnered with Sanofi - which is currently in phase

  • Sanofi buys into AZ drug for preventing RSV infections Sanofi buys into AZ drug for preventing RSV infections

    The deal also includes up to 495m in development and sales milestone payments and focuses on MEDI8897, a follow-up to AZ's already-marketed Synagis (palivizumab) which is the first ... MEDI8897 is a fully-human antibody that has an extended half-life in

More from news
Approximately 2 fully matching, plus 3 partially matching documents found.

Latest Intelligence

  • Deal Watch March 2017 Deal Watch March 2017

    Headline. $m. AstraZeneca/ MedImmune. Sanofi Pasteur. Joint Development. MEDI8897; monoclonal antibody to respiratory syncytial virus in phase IIb.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

OPEN Health Graduate Programme: from OPEN VIE to OPEN Health Medical Communications
Isobel Owens shares her experience of the OPEN Health Graduate Programme from OPEN VIE to OPEN Health Medical Communications...
Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...

Infographics